期刊文献+

荧光原位杂交在慢性粒细胞白血病细胞BCR/ABL融合基因检测中的应用及其意义 被引量:4

The detection of BCR/ABL fusion gene by interphase fluorescence in situ hybridization in patients with chronic myeloid leukemia and its clinical significance
下载PDF
导出
摘要 目的:探讨荧光原位杂交(FISH)技术检测慢性粒细胞白血病(CML)骨髓和外周血细胞的BCR/ABL融合基因的临床价值。方法:应用FISH对正常对照组及CML患者骨髓和外周血细胞BCR/ABL融合基因进行检测和分析。结果:慢性期CML患者骨髓和外周血细胞该融合基因阳性细胞率分别为(61.9±22.3)%和(68.4±19.8)%,加速期为(77.2±16.7)%和(86.8±12.1)%,急变期为(80.6±17.5)%和(81.4±18.0)%,两者细胞中BCR/ABL基因的阳性率未见统计学差异(P>0.05),且骨髓和外周血细胞之间融合基因阳性细胞比率呈直线正相关。同时发现在完全临床缓解患者中,经伊马替尼治疗的CML患者(71.4%)较经干扰素和羟基脲联合治疗者(10.0%)有更高的分子生物学缓解(P<0.05)。结论:通过FISH对CML患者骨髓和(或)外周血细胞融合基因进行监测,有助于CML的诊断、治疗及微小残留白血病的监测。 Objective To explore the clinical significance of the detection of BCR/ABL fusion gene in bone marrow and peripheral blood cells by fluorescence in situ hybridization (FISH) in patients with chronic myeloid leukemia (CML). Methods FISH technique was used to detecte BCR/ABL fusion gene in bone marrow and peripheral blood cells in healthy controls and CML patients. Results The positively expressing rates of BCR/ABL fusion gene in peripheral blood and bone marrow cells were (61.9 ± 22.3)% and (68.4 ± 19.8)% in patients with chronic phase of CML, were (77.2 ± 16.7)% and (86.8 ± 12.1)% in those with accelerating phase, and were (80.6 ± 17.5)% and (81.4 ± 18.0)% in those with blastic crisis, significant difference was not observed (P 0.05). A significant correlation was found between the BCR/ABL positive cells in peripheral blood and in bone marrow samples. Moreover, the higher rate of complete molecular remission was achieved by treating with imatinib than with interferon and hydroxyurea during complete remission phase (P 0.05). Conclusions Detecting BCR/ABL fusion gene in peripheral blood and bone marrow samples by FISH are beneficial to diagnosis, treatment and minimal residual disease monitor in CML.
出处 《实用医学杂志》 CAS 北大核心 2012年第5期825-827,共3页 The Journal of Practical Medicine
基金 湖南省教育厅科研基金资助项目(编号:10C1161)
关键词 白血病 髓系 慢性 BCR-ABL阳性 荧光原位杂交 BCR/ABL 融合基因 Leukemia myelogenous chronic BCR-ABL positive FISH BCR/ABL Fusion gene
  • 相关文献

参考文献3

二级参考文献22

  • 1肖冰,李建勇,潘金兰,马力,仇海荣,吴亚芳,薛永权.多重荧光原位杂交检测骨髓增生异常综合征患者复杂核型异常[J].中华血液学杂志,2005,26(9):513-516. 被引量:12
  • 2ISCN (2005):An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N (eds) ; S. Karger, Basel 2005.
  • 3MeGrattan P, Campbell SL, Cuthbert R, et al. Integration of conventional eytogeneties, comparative genomic hybridization and interphase fluorescence in situ hybridization {or the detection of genomic rearrangements in acute leukemia. J Clin Pathol, 2008, 61 ; 903-908.
  • 4Landstrom AP, Tefferi A. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma, 2006,47 : 397- 402.
  • 5Lira TH, Tien SL, Lim P, et al. The incidence and patterns of BCR/ABL rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ hybridization (FISH). Ann Acad Med Singapore, 2005, 34 : 533- 538.
  • 6Lawce H, Durum C, Unsworth N, et al. BCR-ABL FISH: probes, patterns and prognosis. J Assoc Genet Technol, 2002, 28 :40-46.
  • 7Primo D, Tabernero MD, Rasillo A, et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABI.+ leukemias., incidence and underlying genetic abnormalities. Leukemia, 2003, 17 : 1124- 1129.
  • 8Reid AG, Huntly BJ, Grace C, et al. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloidleukaemia. BrJ Haematol, 2003,121: 419-427.
  • 9Sinclair PB, Nacheva EP, Leversha M, et al. Large deletion at the t(9;22) breakpoint are common and may identify a poorprognosis subgroup of patients with chronic myeloid leukemia. Blood, 2000, 95 : 738-744.
  • 10Cohen N, Rozenfeld Granot G, Hardan I, et al. Subgroup of patients with Philadelphia positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. CancerGenet Cytogenet, 2001,128 : 114-119.

共引文献21

同被引文献38

  • 1宋艳斌,马文丽,冯春琼,毛向明,石嵘,张宝,郑文岭.应用RNA干扰技术抑制K562细胞BCR-ABL基因表达及诱导细胞凋亡[J].基础医学与临床,2005,25(7):620-623. 被引量:6
  • 2吴炜,薛永权,吴亚芳,潘金兰,沈娟.Ph染色体阳性慢性粒细胞白血病衍生9号染色体缺失的FISH研究[J].中华血液学杂志,2006,27(3):183-186. 被引量:12
  • 3王滔明,许建明,胡乃中.Survivin、COX-2和VEGF在胃癌中的表达及其与预后的意义[J].临床消化病杂志,2007,19(1):35-39. 被引量:8
  • 4杨有业,张秀明.临床检验方法学评价[M].北京:人民卫生出版社,2008:118-127.
  • 5GARZON R, VOLINIA S, LIU C G, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia [ J ] . Blood, 2008, 111 (6): 3183-3189.
  • 6POPOVIC R, RIESVECK L E. VELU C S, et al. Regulation of miR-196b by MLL and its overexpression by MLL filsions contributes to immortalization [J ] . Blood, 2009, 113(14): 3314-3322.
  • 7LIU Y, SONG Y B, MAW L, et al. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia [J]. Leuk Res,2013, 37 (3): 349-356.
  • 8ALTIERI D C. Survivin and apoptosis control [ J ] . Adv Cancer Res, 2003, 88: 31-52.
  • 9IBRAHIM A M, MANSOUR I M, WILSON M M, et al. Study of survivin and X-linked inhibi|or of apoptosis protein (XIAP) genes in acute myeloid leukemia (AML) [ J ] . Lab Hematok 2012, 18(1): 1-10.
  • 10CARTER B Z, QIU Y, HUANG X, et al. Survivin is highly expressed in CD34 (+) 38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML [ J ] . Blood, 2012, 120(1): 173-180.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部